Abstract
Introduction: TRAIL is emerging as a novel therapy against multiple cancers. Unfortunately, pancreatic cancer is resistant to TRAIL. Elucidating strategies to overcome this resistance would lead to development of novel therapies against this difficult to treat disease. JAK-2/STAT-3 is a pro-survival pathway which is up-regulated in a variety of cancers. In the current study we have evaluated whether downregulation of JAK-2/STAT-3 pathway can sensitize pancreatic cancer cells to TRAIL induced cell death.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
